Pharmacy partner for clinics
Peptides, sexual wellness and hormone therapy for your practice, through a 503A pharmacy licensed nationwide and an FDA-registered 503B outsourcing facility. U.S.-compounded, third-party tested, with batch-specific COAs.
Two pathways, one partner
Enroll once for patient-specific prescriptions, and add office-use stock whenever you're ready.
Prescribe for a named patient and the pharmacy compounds and ships directly to them, in any state.
Keep product on your shelf for in-clinic administration. No patient prescription needed.
The catalog
Request the full formulary and pricing after enrollment.
Sermorelin, tesamorelin, NAD+, glutathione, GHK-Cu
PT-141, oxytocin, tadalafil, sildenafil, combination capsules
Testosterone, enclomiphene, anastrozole, low-dose naltrexone
Estradiol, estriol, progesterone, testosterone cream
Prescriber-directed programs. Ask about current options.
Minoxidil/finasteride, tretinoin and azelaic acid blends
Availability depends on each product's regulatory status and your clinic's credentialing.
How it works
Send your clinic's details below. We verify licensure and credential your prescribers.
Share your top five products and current prices. Get a side-by-side quote within 24 hours.
Prescriptions and office-use orders go directly to the pharmacy. Processing takes 48 hours.
One contact for onboarding, reorders and anything that goes wrong with an order.
Know what you're buying
Not every peptide vial is the same product. Here's how pharmacy-compounded medication compares with "research use only" (RUO) chemicals.
| 503A | 503B | RUO | |
|---|---|---|---|
| What it is | State-licensed compounding pharmacy | FDA-registered outsourcing facility | Chemical sold "for research only" |
| Prescription | Required, from a credentialed provider for a named patient | Not needed for office use | None; not intended for people |
| Who receives it | The patient, shipped to them or your clinic | Credentialed clinics, for in-office administration | Laboratories and researchers |
| Oversight | State boards of pharmacy, plus federal rules | FDA inspections | No pharmacy oversight |
| Quality standard | USP <795>/<797>, third-party tested, batch-specific COAs | cGMP, third-party tested, batch-specific COAs | Varies by supplier; not pharmacy-regulated |
| Ingredients | Approved-drug components or bulks-list substances | 503B bulks list or FDA-approved drugs | Not limited to pharmacy lists |
| Use in patients | Legal with a valid prescription | Legal for office use | Labeled "not for human use" |
Giving patients a product labeled "not for human use" can put your license and malpractice coverage at risk.
Our 503A and 503B products are U.S.-compounded and third-party tested, with batch COAs and traceable lots.
Patients receive a pharmacy-labeled prescription with instructions, not a chemical vial.
Peptide update · as of October 2026
In July 2026, an FDA advisory committee recommended BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax for 503A compounding. FDA has not finalized them yet, so they are not available for compounding today.
Enroll your clinic
Tell us about your practice. We'll follow up within one business day.
FAQ
No. West Coast Premier Health is an independent sales and onboarding partner. All products are compounded and dispensed by our partner 503A pharmacy or 503B outsourcing facility, which invoice your clinic directly.
Licensed prescribers, clinics and telehealth practices. The pharmacy verifies licensure and credentials each prescriber before the first order.
503A prescriptions are sent straight to the pharmacy and shipped to the patient or your clinic. 503B office-use orders ship to your clinic. Processing takes 48 hours, with 2-day or overnight shipping.
The 503A pharmacy is licensed for patient-specific dispensing in all 50 states.
No. Compounded medications require a prescription from a licensed provider. Patients should talk with their provider.
No. Compounded drugs are not FDA-approved. 503A pharmacies are regulated by state boards of pharmacy under federal rules, and 503B outsourcing facilities are registered with and inspected by FDA.
Not yet. An FDA advisory committee recommended them in July 2026, but FDA has not finalized them for compounding. Enroll and select "Peptide priority list" to hear as soon as they're available.